HIV-2 A-subtype gp125 C2-V3-C3 mutations and their association with CCR5 and CXCR4 tropism

Archives of Virology

Volumn 156, Issue 11, 2011, Pages 1943-1951

  Dimonte, Salvatore ^a   Svicher, Valentina ^a   Salpini, Romina ^a   Ceccherini Silberstein, Francesca ^a   Perno, Carlo Federico ^a,b   Babakir Mina, Muhammed ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GP125 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 2; VIRUS ENVELOPE PROTEIN; VIRUS RECEPTOR;

ARTICLE; CHEMISTRY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN BINDING; PROTEIN MOTIF; VIRAL TROPISM; VIROLOGY;

AMINO ACID MOTIFS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-2; HUMANS; MUTATION; PROTEIN BINDING; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, VIRUS; VIRAL TROPISM;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 80255138143     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-011-1075-z     Document Type: Article

References (69)

1. Barin F, Goudeau A, Romet-Lemonne JL, Choutet P, Chassaigne M (1985) Virus carriage in symptom-free blood donor positive for HTLV-III antibody. Lancet 2: 98.
2. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C (1986) Isolation of a new human retrovirus from West African patients with AIDS. Science 233: 343-346.
3. Pepin J, Morgan G, Dunn D, Gevao S, Mendy M, Gaye I, Scollen N, Tedder R, Whittle H (1991) HIV-2-induced immunosuppression among asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but less so than HIV-1. AIDS 5: 1165-1172.
4. Markovitz DM (1993) Infection with the human immunodeficiency virus type 2. Ann Intern Med 118: 211-218.
5. Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, Whittle H (1998) Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1: 457-468.
6. Soares R, Foxall R, Albuquerque A, Cortesao C, Garcia M, Victorino RM, Sousa AE (2006) Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection. J Virol 80: 12425-12429.
7. Anderson DE, Llenado RA, Torres JV (2004) Humoral immunity and the evolution of HIV-2. Viral Immunol 17: 436-439.
8. Berry N, Jaffar S, Schim van der Loeff M, Ariyoshi K, Harding E, N'Gom PT, Dias F, Wilkins A, Ricard D, Aaby P, Tedder R, Whittle H (2002) Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers. AIDS Res Hum Retrovirus 18: 1167-1173.
9. MacNeil A, Sarr AD, Sankale JL, Meloni ST, Mboup S, Kanki P (2007) Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 81: 5325-5330.
10. Lizeng Q, Nilsson C, Sourial S, Andersson S, Larsen O, Aaby P, Ehnlund M, Bjorling E (2004) Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals. J Virol 78: 7016-7022.
11. Blaak H, Brouwer M, Ran LJ, de Wolf F, Schuitemaker H (1998) In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J Infect Dis 177: 600-610.
12. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, Roederer M, Rowland-Jones SL, Koup RA (2008) Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 38: 350-363.
13. Hamel DJ, Sankale JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, Mboup S, Kanki PJ (2007) Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retrovirus 23: 1189-1196.
14. van der Loeff MF, Awasana AA, Sarge-Njie R, van der Sande M, Jaye A, Sabally S, Corrah T, McConkey SJ, Whittle HC (2006) Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 35: 1322-1328.
15. Campbell-Yesufu OT, Gandhi RT (2011) Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 52: 780-787.
16. Rowland-Jones S (2006) Protective immunity against HIV infection: lessons from HIV-2 infection. Futur Microbiol 1: 427-433.
17. Hoxie JA, Haggarty BS, Bonser SE, Rackowski JL, Shan H, Kanki PJ (1988) Biological characterization of a simian immunodeficiency virus-like retrovirus (HTLV-IV): evidence for CD4-associated molecules required for infection. J Virol 62: 2557-2568.
18. Sattentau QJ, Clapham PR, Weiss RA, Beverley PC, Montagnier L, Alhalabi MF, Gluckmann JC, Klatzmann D (1988) The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule. AIDS 2: 101-105.
19. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
20. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
21. Farzan M, Choe H, Desjardins E, Sun Y, Kuhn J, Cao J, Archambault D, Kolchinsky P, Koch M, Wyatt R, Sodroski J (1998) Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J Virol 72: 7620-7625.
22. Zhu P, Chertova E, Bess J Jr, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH (2003) Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci USA 100: 15812-15817.
23. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
24. Jadhav S, Tripathy S, Kulkarni S, Chaturbhuj D, Ghare R, Bhattacharya J, Paranjape R (2011) Genetic conservation in gp36 transmembrane sequences of Indian HIV type 2 isolates. AIDS Res Hum Retrovirus.
25. Helseth E, Olshevsky U, Furman C, Sodroski J (1991) Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 65: 2119-2123.
26. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673.
27. Eckert DM, Kim PS (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810.
28. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
29. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR (1991) Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253: 71-74.
30. Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A (2006) Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol 80: 7127-7135.
31. Forsell MN, Schief WR, Wyatt RT (2009) Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS 4: 380-387.
32. Blaak H, Boers PH, Gruters RA, Schuitemaker H, van der Ende ME, Osterhaus AD (2005) CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. J Virol 79: 1686-1700.
33. Morner A, Bjorndal A, Leandersson AC, Albert J, Bjorling E, Jansson M (2002) CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates. AIDS Res Hum Retrovirus 18: 193-200.
34. Clapham PR, McKnight A, Weiss RA (1992) Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol 66: 3531-3537.
35. Reeves JD, Hibbitts S, Simmons G, McKnight A, Azevedo-Pereira JM, Moniz-Pereira J, Clapham PR (1999) Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 73: 7795-7804.
36. Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R (2004) The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Biol 340: 9-14.
37. Blumenthal R, Clague MJ, Durell SR, Epand RM (2003) Membrane fusion. Chem Rev 103: 53-69.
38. Bjorling E, Chiodi F, Utter G, Norrby E (1994) Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2. J Immunol 152: 1952-1959.
39. Morner A, Achour A, Norin M, Thorstensson R, Bjorling E (1999) Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2. Virus Res 59: 49-60.
40. Marcelino JM, Borrego P, Rocha C, Barroso H, Quintas A, Novo C, Taveira N (2010) Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. J Virol 84: 12429-12436.
41. Barroso H, Borrego P, Bartolo I, Marcelino JM, Familia C, Quintas A, Taveira N (2011) Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection. PLoS ONE 6: e14548.
42. de Wolf F, Meloen RH, Bakker M, Barin F, Goudsmit J (1991) Characterization of human antibody-binding sites on the external envelope of human immunodeficiency virus type 2. J Gen Virol 72(Pt 6): 1261-1267.
43. Gnann JW Jr, McCormick JB, Mitchell S, Nelson JA, Oldstone MB (1987) Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science 237: 1346-1349.
44. Huang ML, Essex M, Lee TH (1991) Localization of immunogenic domains in the human immunodeficiency virus type 2 envelope. J Virol 65: 5073-5079.
45. Lizeng Q, Skott P, Sourial S, Nilsson C, Andersson SS, Ehnlund M, Taveira N, Bjorling E (2003) Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology 308: 225-232.
46. Mannervik M, Putkonen P, Ruden U, Kent KA, Norrby E, Wahren B, Broliden PA (1992) Identification of B-cell antigenic sites on HIV-2 gp125. J Acquir Immune Defic Syndr 5: 177-187.
47. Norrby E, Putkonen P, Bottiger B, Utter G, Biberfeld G (1991) Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1. AIDS Res Hum Retrovirus 7: 279-285.
48. Schulz TF, Oberhuber W, Hofbauer JM, Hengster P, Larcher C, Gurtler LC, Tedder R, Wachter H, Dierich MP (1989) Recombinant peptides derived from the env-gene of HIV-2 in the serodiagnosis of HIV-2 infections. AIDS 3: 165-172.
49. Zuber M, Samuel KP, Lautenberger JA, Kanki PJ, Papas TS (1990) Bacterially produced HIV-2 env polypeptides specific for distinguishing HIV-2 from HIV-1 infections. AIDS Res Hum Retrovirus 6: 525-534.
50. Marcelino JM, Nilsson C, Barroso H, Gomes P, Borrego P, Maltez F, Rosado L, Doroana M, Antunes F, Taveira N (2008) Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. AIDS 22: 2257-2265.
51. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, Schuitemaker H (1992) Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66: 3183-3187.
52. Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, Paxton WA (2004) Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 78: 524-530.
53. Pollakis G, Kang S, Kliphuis A, Chalaby MI, Goudsmit J, Paxton WA (2001) N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 276: 13433-13441.
54. Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K, Moberg L, Brostrom C, Fenyo EM, Albert J (2005) Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 86: 3385-3396.
55. Taveira NC, Bex F, Burny A, Robertson D, Ferreira MO, Moniz-Pereira J (1994) Molecular characterization of the env gene from a non-syncytium-inducing HIV-2 isolate (HIV-2ALI). AIDS Res Hum Retrovirus 10: 223-224.
56. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
57. Hall TA (1979) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41: 95-98.
58. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57: 289-300.
59. Dimonte S, Mercurio F, Svicher V, D'Arrigo R, Perno CF, Ceccherini-Silberstein F (2011) Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120V3 signatures in the regulation of co-receptor usage. Retrovirology 8: 33.
60. Svicher V, Aquaro S, D'Arrigo R, Artese A, Dimonte S, Alcaro S, Santoro MM, Di PG, Caputo SL, Bellagamba R, Zaccarelli M, Visco-Comandini U, Antinori A, Narciso P, Ceccherini-Silberstein F, Perno CF (2008) Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J Infect Dis 197: 1408-1418.
61. Svicher V, Alteri C, D'Arrigo R, Lagana A, Trignetti M, Lo CS, Callegaro AP, Maggiolo F, Mazzotta F, Ferro A, Dimonte S, Aquaro S, Di PG, Bonora S, Tommasi C, Trotta MP, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F (2009) Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev. Antimicrob Agents Chemother 53: 2816-2823.
62. Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S, Visseaux B, Soulie C, Wirden M, Katlama C, Yeni P, Brun-Vezinet F, Calvez V, Marcelin AG, Descamps D (2011) Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir. Antimicrob Agents Chemother 55: 1754-1757.
63. Leal E, Janini M, Diaz RS (2007) Selective pressures of human immunodeficiency virus type 1 (HIV-1) during pediatric infection. Infect Genet Evol 7: 694-707.
64. Lemey P, Kosakovsky Pond SL, Drummond AJ, Pybus OG, Shapiro B, Barroso H, Taveira N, Rambaut A (2007) Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLoS Comput Biol 3: e29.
65. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73: 10489-10502.
66. Yang W, Bielawski JP, Yang Z (2003) Widespread adaptive evolution in the human immunodeficiency virus type 1 genome. J Mol Evol 57: 212-221.
67. Isaka Y, Sato A, Miki S, Kawauchi S, Sakaida H, Hori T, Uchiyama T, Adachi A, Hayami M, Fujiwara T, Yoshie O (1999) Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology 264: 237-243.
68. Santos-Costa Q, Parreira R, Moniz-Pereira J, Azevedo-Pereira JM (2009) Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates. J Med Virol 81: 1869-1881.
69. Santos-Costa Q, Mansinho K, Moniz-Pereira J, Azevedo-Pereira JM (2009) Characterization of HIV-2 chimeric viruses unable to use CCR5 and CXCR4 coreceptors. Virus Res 142: 41-50.